Optoacoustic imaging firm Seno Medical Instruments is highlighting clinical results published in Radiology about its Imagio breast imaging optoacoustic ultrasound (OA/US) technology.
Researchers at the University of Texas Southwestern Medical Center in Dallas found that OA/US has the potential to identify characteristics that distinguish luminal cancers from those classified as triple negatives and HER2+.
A group led by Dr. Basak Dogan assessed 2,055 breast masses in 1,972 women who underwent a prebiopsy OA/US exam using Imagio. Of those, 652 masses in 629 women showed invasive cancer at final pathology, the company said (Radiology, July 9, 2019).
By identifying morphological and functional features such as internal blood vessels and hemoglobin, OA/US helped distinguish breast cancer subtypes from flagged cancers that have the highest likelihood for aggressive growth and metastasis, according to the firm.
